Abstract
KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. Primary analysis of this phase II trial (data as of January 19, 2021) showed promising efficacy and well tolerated safety in advanced NSCLC pts. Herein, we present an updated analysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have